Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VKTX – Viking Therapeutics, Inc.

Float Short %

20.93

Margin Of Safety %

Put/Call OI Ratio

0.25

EPS Next Q Diff

-0.13

EPS Last/This Y

-1.6

EPS This/Next Y

-1.11

Price

37.04

Target Price

93.39

Analyst Recom

1.11

Performance Q

53.95

Relative Volume

0.56

Beta

0.69

Ticker: VKTX



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13VKTX39.010.270.29308251
2025-11-14VKTX39.090.280.32310674
2025-11-17VKTX38.20.270.25293500
2025-11-18VKTX37.730.270.12298900
2025-11-19VKTX36.040.270.18301404
2025-11-20VKTX34.270.270.11307655
2025-11-21VKTX34.250.280.29305539
2025-11-24VKTX34.650.240.22239708
2025-11-25VKTX35.480.240.15249433
2025-11-26VKTX36.30.240.40252884
2025-12-01VKTX34.580.240.20242887
2025-12-02VKTX33.880.250.17243659
2025-12-03VKTX35.40.250.09246646
2025-12-04VKTX38.570.240.17253633
2025-12-05VKTX38.550.250.33263679
2025-12-08VKTX37.980.240.45256246
2025-12-09VKTX37.290.250.33262138
2025-12-10VKTX37.530.240.17265672
2025-12-11VKTX37.20.250.60266712
2025-12-12VKTX37.040.250.20270349
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13VKTX39.00-177.3- -2.61
2025-11-14VKTX39.10-177.3- -2.61
2025-11-17VKTX38.20-177.3- -2.61
2025-11-18VKTX37.71-177.3- -2.61
2025-11-19VKTX36.04-177.3- -2.61
2025-11-20VKTX34.25-177.3- -2.61
2025-11-21VKTX34.26-177.3- -2.61
2025-11-24VKTX34.63-177.3- -2.61
2025-11-25VKTX35.46-177.3- -2.57
2025-11-26VKTX36.30-177.3- -2.57
2025-12-01VKTX34.54-180.3- -2.61
2025-12-02VKTX33.88-180.3- -2.61
2025-12-03VKTX35.41-180.3- -2.61
2025-12-04VKTX38.57-180.3- -2.61
2025-12-05VKTX38.55-180.3- -2.61
2025-12-08VKTX37.98-180.3- -2.61
2025-12-09VKTX37.28-180.3- -2.61
2025-12-10VKTX37.53-180.3- -2.61
2025-12-11VKTX37.19-180.3- -2.61
2025-12-12VKTX37.04-180.3- -2.61
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13VKTX-4.12-4.3722.05
2025-11-14VKTX-4.12-4.3722.05
2025-11-17VKTX-4.15-0.5722.05
2025-11-18VKTX-4.15-0.5722.05
2025-11-19VKTX-4.15-0.5722.05
2025-11-20VKTX-4.15-0.5722.05
2025-11-21VKTX-4.15-0.5722.05
2025-11-24VKTX-4.15-2.8022.01
2025-11-25VKTX-4.39-2.8022.01
2025-11-26VKTX-4.39-2.8022.57
2025-12-01VKTX-4.39-3.0722.57
2025-12-02VKTX-4.39-3.0722.57
2025-12-03VKTX-4.39-3.0722.57
2025-12-04VKTX-4.39-3.0722.57
2025-12-05VKTX-4.39-3.0722.57
2025-12-08VKTX-4.39-2.8422.57
2025-12-09VKTX-4.39-2.8422.57
2025-12-10VKTX-4.39-2.8420.93
2025-12-11VKTX-4.39-2.8420.93
2025-12-12VKTX-4.39-2.8420.93
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="VKTX" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

-0.81

Avg. EPS Est. Current Quarter

-0.9

Avg. EPS Est. Next Quarter

-0.94

Insider Transactions

-4.39

Institutional Transactions

-2.84

Beta

0.69

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

10

Growth Score

18

Sentiment Score

64

Actual DrawDown %

62.7

Max Drawdown 5-Year %

-78.9

Target Price

93.39

P/E

Forward P/E

PEG

P/S

P/B

5.85

P/Free Cash Flow

EPS

-2.12

Average EPS Est. Cur. Y​

-2.61

EPS Next Y. (Est.)

-3.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.56

Return on Equity vs Sector %

-60.2

Return on Equity vs Industry %

-45.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”VKTX” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VKTX” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VKTX” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VKTX” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VKTX” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VKTX” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VKTX” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Viking Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 50
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
stock quote shares VKTX – Viking Therapeutics, Inc. Stock Price stock today
news today VKTX – Viking Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics, Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics, Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading